Skip to Main Content

++

ICD-9 : 701.2 • ICD-10 : L 83   Image not available. Image not available. Image not available. Image not available. Image not available. Image not available.

++

  • Asymmetric velvety thickening and hyperpigmentation of the skin, chiefly on the neck, axilla, groins, and other body folds.
  • May be hyperkeratotic and associated with skin tags.
  • A cutaneous marker related to heredity, obesity, endocrine disorders (particularly diabetes), drug administration, and malignancy.
  • Insidious onset; in malignancy, rapid.

++

Classification

++

Type 1: Hereditary Benign AN

++

No associated endocrine disorder.

++

Type 2: Benign AN

++

Endocrine disorders associated with insulin resistance: insulin-resistant type II diabetes mellitus, hyperandrogenic states, acromegaly/gigantism, Cushing disease, hypogonadal syndromes with insulin resistance, Addison disease, hypothyroidism.

++

Type 3: Pseudo‐AN

++

Associated with obesity; more common in patients with darker pigmentation. Common in metabolic syndrome. Obesity produces insulin resistance.

++

Type 4: Drug-Induced AN

++

Nicotinic acid in high dosage, stilbestrol in young males, glucocorticoid therapy, diethylstilbestrol/oral contraceptive, growth hormone therapy.

++

Type 5: Malignant AN

++

Paraneoplastic, usually adenocarcinoma of gastrointestinal or genitourinary tract; less commonly, lymphoma (see Section 18).

++

Epidemiology

++

Age of Onset

++

Type 1: during childhood or puberty; other types dependent on associated conditions.

++

Etiology and Pathogenesis

++

Dependent on associated disorder. In a subset of women with hyperandrogenism and insulin intolerance and AN, loss-of-function mutation in the insulin receptor or anti-insulin receptor antibodies can be found (types A and B). It is postulated that excess growth factor stimulation in the skin leads to proliferation of keratinocytes and fibroblasts. In hyperinsulinemia AN, excess insulin binding to insulin–like growth factor 1 receptor and fibroblast growth factor receptor has also been implicated. In malignancy-associated AN, transforming growth factor β released from tumor cells may stimulate keratinocyte proliferation via epidermal growth factor receptors.

++

Clinical Manifestation

++

Insidious onset; first visible change is darkening of pigmentation.

++

Skin Lesions

++

All types of AN: Darkening of pigmentation, skin appears dirty (Fig. 5-1). As skin thickens, appears velvety; skin lines accentuated; surface becomes rugose, mammillated. Type 3: velvety patch on inner, upper thigh at site of chafing; often has many skin tags in body folds and neck. Type 5: hyperkeratosis and hyperpigmentation more pronounced (see Fig. 18-16). Hyperkeratosis of palms/soles, with accentuation of papillary markings: “Tripe hands” (see Fig. 18-18), involvement of oral mucosa and vermilion border of lips (see Fig. 18-17).

++
Figure 5-1
Graphic Jump Location

Acanthosis nigricans Velvety, dark-brown to gray thickening of the skin of the armpit with prominent skin folds and feathered edges in a 30-year-old obese woman from the Middle East. There were similar changes on the neck, the antecubital ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.